performing clinical trials for vaccine that can kill cancer
Συγγραφέας iator Γράφτηκε στις ,
PRESS RELEASE
Tailored to treat 90 percent of cancers
Hadassah University Medical Center performing clinical trials for vaccine that can kill cancer
The Hadassah University Medical Center in Jerusalem is currently in advanced clinical trials for a therapeutic vaccine, ImMucim, that has been formulated to ‘train’ the immune system to seek and destroy malignant cells that have already invaded the body. Principal investigator in these clinical trials is Dr. Michael Y Shapira, MD, of Hadassah.
The ImMucim vaccine was developed by Vaxil BioTherapeutics, a pharmaceutical company in Israel, and according to CEO Julian Levy, “this therapeutic vaccine doesn’t prevent cancer from invading, but activates and enhances the body’s natural immune system to seek and destroy cancer cells already present in the body, such as those lingering after cancer surgery.”
The vaccine is based on a drug platform that can be tailored to treat not only 90 percent of cancers, but also diseases such as tuberculosis, an infection that is cropping up in developing nations. The drug is currently being tested by Hadassah University Medical Center against a blood cancer called multiple myeloma, and is said to present no side effects, and can be taken indefinitely. It is also designed to overcome cancer cells that mutate, rendering other drugs ineffective.
Depending on the outcome of the clinical trials, the vaccine could be ready and marketable within the next six years. This could have major implications for the treatment of leading killers, such as prostate and breast cancer. For patients who wish to avoid surgery for prostate cancer, this vaccine could be a helpful tool in prolonging their lives.
